Sublingual Dexmedetomidine Treatment Effect Size

Recently, sublingual dexmedetomidine was approved by the FDA for the treatment of agitation associated with schizophrenia or bipolar I or II disorder after it significantly reduced episodes compared with placebo in the pivotal SERENITY I and SERENITY II trials.